Randomized phase II study of aprepitant in patients with colorectal cancer receiving FOLFOX, FOLFIRI, or XELOX chemotherapy regimen.

ABSTRACT: Interventions: Aprepitant; 125 mg PO on day 1 Aprepitant; 80 mg PO on days 2 to 3 5HT3-receptor antagonist; IV on day 1 Dexamethasone; 6.6 mg IV on day 1 Dexamethasone; 4 mg PO on days 2 to 3 5HT3-receptor antagonist; IV on day 1 Dexamethasone; 9.9 mg IV on day 1 Dexamethasone; 8 mg PO on days 2 to 3 Primary outcome(s): The percentage of patients with complete response (defined as no emetic episode and no rescue therapy) Study Design: Parallel Randomized

DISEASE(S): Colon And Rectal Cancer

PROVIDER: 2622198 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR